Chargement de la fiche…
Chargement de la fiche…
Praticien hospitalier
Photo : Chabe01, CC BY-SA 4.0, Wikimedia Commons
Dans les médias
Vous êtes Dr Rakiba Belkhir ? Présentation, expertises, actes, site du cabinet : faites de cette fiche la page de votre cabinet.
Configurer votre fiche gratuitement →Dr Rakiba Belkhir est rhumatologue à Le Kremlin-Bicêtre (94275). Il consulte notamment à GHU APHP UPS SITE KREMLIN BICETRE APHP, 78 Avenue DU GENERAL LECLERC, 94275 Le Kremlin-Bicêtre (2 lieux au total).
Consulter
GHU APHP UPS SITE KREMLIN BICETRE APHP
Dr Rakiba Belkhir, c'est vous ?
Faites de cette fiche la page de votre cabinet.
78 Avenue DU GENERAL LECLERC, 94275 Le Kremlin-Bicêtre
Hospitalier
INSTITUT GUSTAVE ROUSSY
39B Rue CAMILLE DESMOULINS, 94805 Villejuif
Hospitalier
Pour aller plus loin
Remboursement
Pratique
Thèmes de publication
Domaines déduits des publications référencées sur PubMed.
Faits issus de registres publics et des déclarations du praticien — aucun classement.
DES Rhumatologie · Rhumatologie (SM) — Diplôme d'études spécialisées
DE Docteur en médecine — Capacité / certificat d'études spéciales
Les plus citées
2017Annals of the rheumatic diseases177 citations
Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment
2017European journal of cancer (Oxford, England : 1990)163 citations
Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis
2024Nature medicine121 citations
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
Contenus publics où le nom du praticien apparaît (YouTube, Google Actualités).
En bref
Dr Rakiba Belkhir exerce dans 2 lieux : GHU APHP UPS SITE KREMLIN BICETRE APHP, 78 Avenue DU GENERAL LECLERC, 94275 Le Kremlin-Bicêtre et INSTITUT GUSTAVE ROUSSY, 39B Rue CAMILLE DESMOULINS, 94805 Villejuif. Adresses issues de l'Annuaire Santé (ANS).
Par téléphone au 01 45 21 21 21 (numéro publié à l'Annuaire Santé). Un lien de recherche Doctolib est proposé sur cette page : si le praticien y est inscrit, son profil figure normalement parmi les résultats.
Identité, diplômes et lieux d'exercice : Annuaire Santé (ANS, licence ouverte). Conventionnement et carte Vitale : Assurance Maladie. Publications : bases scientifiques publiques (PubMed, HAL, OpenAlex), affichées seulement si le nom du praticien figure parmi les auteurs. Le praticien peut corriger sa fiche ou en demander le retrait à tout moment ; en cas d'homonymie, signalez-le.
Autour du cabinet
Rhumatologues au Kremlin-Bicêtre →Rhumatologues en Val-de-Marne (94) →
Vous pouvez aussi demander le retrait de la fiche.
Aperçu de votre présentation
Rhumatologue à Le Kremlin-Bicêtre, j'accompagne…
Exemple : vous choisissez vos propres domaines.
Association between anti-SSA/SSB antibody profiles and patient-reported outcomes in primary Sjögren's disease
2026RMD openPubMed
Evaluation of pregnancy outcomes in patients with rheumatoid arthritis compared with the general population: results from a French national prospective and matched study
2026RMD openPubMed
Impact of postpartum on patients with rheumatoid arthritis and spondyloarthritis: an ancillary analysis of the GR2 prospective cohort
2025Rheumatology (Oxford, England)PubMed
Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort
2022Joint bone spinePubMed
Lack of association between the TNFAIP3 rs2230926 variant and rheumatoid arthritis-associated lymphoma
2021Rheumatology (Oxford, England)PubMed
Peripheral ulcerative keratitis in rheumatoid arthritis patients taking tocilizumab: paradoxical manifestation or insufficient efficacy?
2021RMD openPubMed
Lymphoma complicating rheumatoid arthritis: results from a French case-control study
2020Rheumatology (Oxford, England)PubMed
Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy
2018Rheumatology (Oxford, England)PubMed
Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection
2017Annals of the rheumatic diseasesPubMed
Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment
2024Annals of the rheumatic diseasesPubMed
Obinutuzumab in patients with Sjogren's disease immunised against rituximab
2022Arthritis & rheumatology (Hoboken, N.J.)PubMed
Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases
2022RMD openPubMed
Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses
2021Rheumatology (Oxford, England)PubMed
Peripheral ulcerative keratitis in rheumatoid arthritis patients taking tocilizumab: paradoxical manifestation or insufficient efficacy?
2020Annals of the rheumatic diseasesPubMed
Efficacity of a sequential treatment by anti-CD 20 monoclonal antibody and belimumab in type II cryoglobulinaemia associated with primary Sjögren syndrome refractory to rituximab alone
2020Rheumatology (Oxford, England)PubMed
Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy
2018Rheumatology (Oxford, England)PubMed
Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection
2016LupusPubMed
Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease
2026Presse medicale (Paris, France : 1983)PubMed
Immune checkpoint inhibitor-induced joint involvement
2026Presse medicale (Paris, France : 1983)PubMed
Sicca induced by immune checkpoint inhibitors
2025LeukemiaPubMed
Molecular profiling and risk stratification in solitary bone plasmacytoma
2024HaematologicaPubMed
Clonal CD8(+) T-cell expansion is associated with complete response to elranatamab in refractory multiple myeloma
2024Bone reportsPubMed
High rate of progression to symptomatic multiple myeloma in patients with smoldering myeloma and isolated osteoporotic vertebral fracture
2023HaematologicaPubMed
Chemotherapy in solitary bone plasmacytoma to prevent evolution to multiple myeloma
2022RMD openPubMed
Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study
2021Journal of hematology & oncologyPubMed
Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls
2023HaematologicaPubMed
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study
2020European journal of cancer (Oxford, England : 1990)PubMed
The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study
2017European journal of cancer (Oxford, England : 1990)PubMed
Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis
2026RMD openPubMed
Impact of postpartum on patients with rheumatoid arthritis and spondyloarthritis: an ancillary analysis of the GR2 prospective cohort
2026Annals of the rheumatic diseasesPubMed
Evaluation of pregnancy outcomes in patients with spondyloarthritis compared to the general population: results from a French national prospective and matched study
2017The Journal of rheumatologyPubMed
Takayasu Arteritis and Spondyloarthritis: Coincidence or Association? A Study of 14 Cases
2025HaematologicaPubMed
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program
2023HaematologicaPubMed
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study
2026 · Article
Evaluation of pregnancy outcomes in patients with rheumatoid arthritis compared with the general population: results from a French national prospective and matched study
2026 · Article
Impact of postpartum on patients with rheumatoid arthritis and spondyloarthritis: an ancillary analysis of the GR2 prospective cohort
2026 · Article
Evaluation of pregnancy outcomes in patients with spondyloarthritis compared to the general population: results from a French national prospective and matched study
2025 · Article
Comment on: Hydroxychloroquine levels in pregnancy and materno–fetal outcomes in Systemic Lupus Erythematosus patients: Reply
2024 · Article
Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort
2024 · Article
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
2024 · Article
Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts
2024 · Article
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program
Publications affichées uniquement lorsque le nom du praticien figure parmi les auteurs. Une erreur d'homonymie ? Signalez-la depuis le lien en bas de page.